共 101 条
[1]
Fisher B(1996)Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88 1529-42
[2]
Dignam J(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717
[3]
Bryant J(2004)Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 858-68
[4]
DeCillis A(1994)The influence of young age on outcome in early stage breast cancer Int J Radiat Oncol Biol Phys 30 23-33
[5]
Wickerham DL(2007)Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society J Clin Oncol 25 2360-8
[6]
Wolmark N(2015)Adjuvant ovarian suppression in premenopausal breast cancer N Engl J Med 372 436-46
[7]
Fisher B(2014)The basic facts of korean breast cancer in 2011: results of a nationwide survey and breast cancer registry database J Breast Cancer 17 99-106
[8]
Jeong J(2002)Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5 J Clin Oncol 20 4621-7
[9]
Bryant J(2007)Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII J Clin Oncol 25 263-70
[10]
Anderson S(2007)Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials Lancet 369 1711-23